Adagio Medical FY2025 net loss narrows 66.55% to $25 million; revenue falls to no revenue

Reuters

Mar 27

Adagio Medical FY2025 net loss narrows 66.55% to $25 million; revenue falls to no revenue

Adagio published a fourth-quarter and full-year 2025 earnings press release.
Fourth-quarter revenue was no revenue, while net loss narrowed to USD 3.3 million.
Fourth-quarter R&D expense fell 34.6% to USD 2.2 million, driven by lower quality assurance costs, fewer R&D projects and reduced headcount.
Fourth-quarter SG&A expense declined 58.6% to USD 1.7 million, primarily due to the absence of SPAC-related corporate expenses and lower payroll and personnel costs from reduced headcount.
Cash and cash equivalents were USD 17.1 million at year-end; management said enrollment was completed in the 209-patient FULCRUM-VT pivotal IDE trial and cited preliminary results showing 97% acute effectiveness.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagio Medical Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603270800BIZWIRE_USPR_____20260327_BW740735) on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2622826478"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622826478\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622826478?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622826478","market":"us","top_or_hot":-1,"title":"Adagio Medical FY2025 net loss narrows 66.55% to $25 million; revenue falls to no revenue","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adagio Medical FY2025 net loss narrows 66.55% to $25 million; revenue falls to no revenue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Adagio published a fourth-quarter and full-year 2025 earnings press release.\n        </li>\n<li>\n          Fourth-quarter revenue was no revenue, while net loss narrowed to USD 3.3 million.\n        </li>\n<li>\n          Fourth-quarter R&amp;D expense fell 34.6% to USD 2.2 million, driven by lower quality assurance costs, fewer R&amp;D projects and reduced headcount.\n        </li>\n<li>\n          Fourth-quarter SG&amp;A expense declined 58.6% to USD 1.7 million, primarily due to the absence of SPAC-related corporate expenses and lower payroll and personnel costs from reduced headcount.\n        </li>\n<li>\n          Cash and cash equivalents were USD 17.1 million at year-end; management said enrollment was completed in the 209-patient FULCRUM-VT pivotal IDE trial and cited preliminary results showing 97% acute effectiveness.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagio Medical Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603270800BIZWIRE_USPR_____20260327_BW740735) on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adagio Medical FY2025 net loss narrows 66.55% to $25 million; revenue falls to no revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdagio Medical FY2025 net loss narrows 66.55% to $25 million; revenue falls to no revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-27 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adagio Medical FY2025 net loss narrows 66.55% to $25 million; revenue falls to no revenue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Adagio published a fourth-quarter and full-year 2025 earnings press release.\n        </li>\n<li>\n          Fourth-quarter revenue was no revenue, while net loss narrowed to USD 3.3 million.\n        </li>\n<li>\n          Fourth-quarter R&amp;D expense fell 34.6% to USD 2.2 million, driven by lower quality assurance costs, fewer R&amp;D projects and reduced headcount.\n        </li>\n<li>\n          Fourth-quarter SG&amp;A expense declined 58.6% to USD 1.7 million, primarily due to the absence of SPAC-related corporate expenses and lower payroll and personnel costs from reduced headcount.\n        </li>\n<li>\n          Cash and cash equivalents were USD 17.1 million at year-end; management said enrollment was completed in the 209-patient FULCRUM-VT pivotal IDE trial and cited preliminary results showing 97% acute effectiveness.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagio Medical Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603270800BIZWIRE_USPR_____20260327_BW740735) on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XTNT","symbol_name":"Xtant Medical Holdings Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL83xkXN:1","article_id":"2622826478","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622826478","pubTimestamp":1774612865,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Adagio published a fourth-quarter and full-year 2025 earnings press release.Fourth-quarter revenue was no revenue, while net loss narrowed to USD 3.3 million.Fourth-quarter R&D expense fell 34.6% to USD 2.2 million, driven by lower quality assurance costs, fewer R&D projects and reduced headcount.Fourth-quarter SG&A expense declined 58.6% to USD 1.7 million, primarily due to the absence of SPAC-related corporate expenses and lower payroll and personnel costs from reduced headcount.Cash and cash equivalents were USD 17.1 million at year-end; management said enrollment was completed in the 209-patient FULCRUM-VT pivotal IDE trial and cited preliminary results showing 97% acute effectiveness.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XTNT":"Xtant Medical Holdings Inc","ADGM":"Adagio Medical Holdings, Inc.","BK4198":"医疗保健用品","BK4082":"医疗保健设备"},"translate_title":"Adagio Medical 2025财年净亏损收窄66.55%至2500万美元；收入降至无收入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADGM":0.9,"XTNT":0.9},"content_text":"Adagio Medical FY2025 net loss narrows 66.55% to $25 million; revenue falls to no revenue\n    \n\n\n          Adagio published a fourth-quarter and full-year 2025 earnings press release.\n        \n\n          Fourth-quarter revenue was no revenue, while net loss narrowed to USD 3.3 million.\n        \n\n          Fourth-quarter R&D expense fell 34.6% to USD 2.2 million, driven by lower quality assurance costs, fewer R&D projects and reduced headcount.\n        \n\n          Fourth-quarter SG&A expense declined 58.6% to USD 1.7 million, primarily due to the absence of SPAC-related corporate expenses and lower payroll and personnel costs from reduced headcount.\n        \n\n          Cash and cash equivalents were USD 17.1 million at year-end; management said enrollment was completed in the 209-patient FULCRUM-VT pivotal IDE trial and cited preliminary results showing 97% acute effectiveness.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagio Medical Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603270800BIZWIRE_USPR_____20260327_BW740735) on March 27, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}